Literature DB >> 1835705

The anti-diabetogenic effect of essential fatty acid deficiency in multiple low-dose streptozotocin-treated mice persists if essential fatty acid repletion occurs outside of a brief window of susceptibility.

J R Wright1, B Haliburton, H Russell, M Henry, R Fraser, H W Cook.   

Abstract

We have previously shown that essential fatty acid deficiency prevents diabetes mellitus and ameliorates insulitis in multiple low-dose streptozotocin-treated male CD-1 mice and that repletion with 99% pure methyl linoleate 3 days after the last injection causes diabetes. In the present study, we examined whether repletion of low-dose streptozotocin-treated deficient mice will cause diabetes whenever repletion occurs. Essential fatty acid deficiency was induced by dietary manipulation and was confirmed biochemically. Groups of deficient mice were repleted 6 h, 1 week, 2 weeks, 4 weeks and 8 weeks after the last low-dose streptozotocin treatment; the incidence of diabetes (i.e., non-fasting plasma glucose levels greater than 11.2 mmol/l) and group mean plasma glucose levels were 93% (19.4 mmol/l), 37% (14.8 mmol/l), 40% (13.7 mmol/l), 20% (9.0 mmol/l), and 8% (7.8 mmol/l) respectively. The incidence and mean glucose levels for low-dose streptozotocin-induced control chow-fed and non-repleted essential fatty acid deficient CD-1 mice were 100% (30.2 mmol/l) and 0% (4.2 mmol/l). The incidence and severity of insulitis also decreased with increasing repletion intervals. These results demonstrate a brief window of susceptibility of less than 8 weeks duration during which repletion will initiate an autoimmune response directed at low-dose streptozotocin-induced Beta-cell neoantigens in low-dose streptozotocin-treated essential fatty acid deficient mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835705     DOI: 10.1007/bf00401515

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  33 in total

1.  Essential fatty acid deficiency inhibits the in vivo generation of leukotriene B4 and suppresses levels of resident and elicited leukocytes in acute inflammation.

Authors:  J B Lefkowith
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

2.  Streptozotocin-induced pancreatic insulitis in mice. Morphologic and physiologic studies.

Authors:  A A Like; M C Appel; R M Williams; A A Rossini
Journal:  Lab Invest       Date:  1978-04       Impact factor: 5.662

Review 3.  The role of eicosandoids in inflammation.

Authors:  G A Higgs
Journal:  Prog Lipid Res       Date:  1986       Impact factor: 16.195

4.  Analysis of 22 immunomodulatory substances for efficacy in low-dose streptozotocin-induced diabetes.

Authors:  H Kolb; M Oschilewski; U Oschilewski; E Schwab; C M Moumé; B Greulich; V Burkart; J Zielasek; U Kiesel
Journal:  Diabetes Res       Date:  1987-09

5.  Rat superoxide dismutases. Purification, labeling, immunoassay, and tissue concentration.

Authors:  K Asayama; I M Burr
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

6.  Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin.

Authors:  K C Herold; A G Montag; F W Fitch
Journal:  Diabetes       Date:  1987-07       Impact factor: 9.461

7.  Islet implantation normalises hyperglycaemia caused by streptozotocin-induced insulitis. Experiments in mice.

Authors:  A Andersson
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

8.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.

Authors:  A A Like; A A Rossini
Journal:  Science       Date:  1976-07-30       Impact factor: 47.728

9.  Genetic control of low-dose streptozotocin-induced autoimmune diabetes in mice.

Authors:  U Kiesel; F W Falkenberg; H Kolb
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

10.  Inhibition of streptozocin-induced insulitis and diabetes with lobenzarit in CD-1 mice.

Authors:  R Iwakiri; S Nagafuchi
Journal:  Diabetes       Date:  1989-05       Impact factor: 9.461

View more
  2 in total

1.  Immunophenotyping of insulitis in control and essential fatty acid deficient mice treated with multiple low-dose streptozotocin.

Authors:  R B Fraser; G Rowden; P Colp; J R Wright
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

2.  Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in naive and cyclosporin-treated low-responder murine strains.

Authors:  J R Wright; R B Fraser; S Kapoor; H W Cook
Journal:  Acta Diabetol       Date:  1995-06       Impact factor: 4.280

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.